Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) will announce its financial and operational results for Q1 2022 on May 10, 2022, before the market opens. The management team will conduct a conference call/webcast at 8:30 am ET to discuss the results and provide a business update. Interested parties can participate by dialing +1-877-407-9170 or accessing the audio webcast via Aurinia’s corporate website. Aurinia is dedicated to developing therapies for serious diseases, having introduced the first FDA-approved oral treatment for lupus nephritis in January 2021.

Positive

• Aurinia is set to release Q1 2022 financial results, which may indicate growth or positive performance.
• The company has an established history with the FDA-approved oral therapy for lupus nephritis, potentially boosting investor confidence.

Negative

• None.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Interested participants can dial +1-877-407-9170 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005587/en/

Investor and Corporate

Dana Lynch, IR & Corporate Communications

dlynch@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When will Aurinia Pharmaceuticals release its Q1 2022 results?

Aurinia Pharmaceuticals will release its Q1 2022 financial results on May 10, 2022.

What time is the Aurinia Pharmaceuticals conference call for Q1 2022 results?

The conference call for Aurinia Pharmaceuticals' Q1 2022 results will be held at 8:30 am ET on May 10, 2022.

How can I access Aurinia Pharmaceuticals' Q1 2022 results webcast?

You can access the Q1 2022 results webcast on Aurinia's corporate website under the 'News/Events' section.

What significant product has Aurinia Pharmaceuticals introduced?

Aurinia Pharmaceuticals introduced the first FDA-approved oral therapy for lupus nephritis in January 2021.

What is the stock symbol for Aurinia Pharmaceuticals?

The stock symbol for Aurinia Pharmaceuticals is AUPH.